Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:DCGO NASDAQ:QIPT NASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$7.60-2.9%$8.12$3.44▼$34.40$55.71M0.98199,870 shs17,376 shsDCGODocGo$1.17-2.2%$1.50$1.12▼$5.68$113.17M0.95791,078 shs981,886 shsQIPTQuipt Home Medical$2.41-3.8%$2.49$1.35▼$3.27$104.47M0.6536,972 shs202,927 shsSERASera Prognostics$3.03-5.3%$2.91$1.37▼$9.13$114.14M0.97197,351 shs30,960 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+1.03%+1.69%-15.66%+26.86%-76.13%DCGODocGo-4.76%-6.25%-24.05%-19.46%-62.50%QIPTQuipt Home Medical-2.34%-4.94%-3.47%+33.69%-6.72%SERASera Prognostics+1.59%+2.24%+3.23%+12.68%-50.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$7.60-2.9%$8.12$3.44▼$34.40$55.71M0.98199,870 shs17,376 shsDCGODocGo$1.17-2.2%$1.50$1.12▼$5.68$113.17M0.95791,078 shs981,886 shsQIPTQuipt Home Medical$2.41-3.8%$2.49$1.35▼$3.27$104.47M0.6536,972 shs202,927 shsSERASera Prognostics$3.03-5.3%$2.91$1.37▼$9.13$114.14M0.97197,351 shs30,960 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+1.03%+1.69%-15.66%+26.86%-76.13%DCGODocGo-4.76%-6.25%-24.05%-19.46%-62.50%QIPTQuipt Home Medical-2.34%-4.94%-3.47%+33.69%-6.72%SERASera Prognostics+1.59%+2.24%+3.23%+12.68%-50.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.50Moderate Buy$32.50327.63% UpsideDCGODocGo 2.00Hold$3.24175.77% UpsideQIPTQuipt Home Medical 2.00Hold$3.1530.98% UpsideSERASera Prognostics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BDSX, DCGO, SERA, and QIPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BDSXBiodesixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DCGODocGoWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025QIPTQuipt Home MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SERASera PrognosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025DCGODocGoZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/27/2025BDSXBiodesixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DCGODocGoWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025QIPTQuipt Home MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SERASera PrognosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$30.00 ➝ $20.008/21/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$1.45 ➝ $1.60(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$71.32M0.78N/AN/A$2.87 per share2.65DCGODocGo$616.55M0.19$0.39 per share2.98$3.09 per share0.38QIPTQuipt Home Medical$245.91M0.42$0.95 per share2.52$2.49 per share0.97SERASera Prognostics$80K1,426.75N/AN/A$1.40 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$42.93M-$5.80N/AN/AN/A-53.66%-269.67%-43.94%11/7/2025 (Estimated)DCGODocGo$19.99M-$0.19N/A14.68N/A-4.20%-3.26%-2.24%11/6/2025 (Estimated)QIPTQuipt Home Medical-$6.76M-$0.24N/AN/AN/A-4.30%-9.78%-4.23%12/15/2025 (Estimated)SERASera Prognostics-$32.90M-$0.85N/AN/AN/A-30,306.48%-45.86%-34.31%11/5/2025 (Estimated)Latest BDSX, DCGO, SERA, and QIPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/7/2025Q3 2025BDSXBiodesix-$1.60N/AN/AN/AN/AN/A11/6/2025Q3 2025DCGODocGo-$0.09N/AN/AN/A$69.96 millionN/A11/5/2025Q3 2025SERASera Prognostics-$0.19N/AN/AN/A$0.10 millionN/A8/11/2025Q3 2025QIPTQuipt Home Medical$0.03-$0.07-$0.10-$0.07$80.37 million$58.30 million8/7/2025Q2 2025BDSXBiodesix-$1.40-$1.60-$0.20-$0.08$18.47 million$20.02 million8/7/2025Q2 2025DCGODocGo-$0.06-$0.11-$0.05-$0.11$77.58 million$80.42 million8/6/2025Q2 2025SERASera Prognostics-$0.21-$0.16+$0.05-$0.16$0.05 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix41.112.142.14DCGODocGoN/A2.362.36QIPTQuipt Home Medical0.711.150.75SERASera PrognosticsN/A1.731.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%DCGODocGo56.44%QIPTQuipt Home Medical42.85%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix30.10%DCGODocGo3.80%QIPTQuipt Home Medical13.40%SERASera Prognostics13.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix2207.33 million5.13 millionOptionableDCGODocGo4,40797.81 million94.09 millionOptionableQIPTQuipt Home Medical1,20043.44 million37.62 millionOptionableSERASera Prognostics12037.67 million32.59 millionOptionableBDSX, DCGO, SERA, and QIPT HeadlinesRecent News About These CompaniesSera Prognostics (NASDAQ:SERA) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9 at 4:47 AM | marketbeat.comSera Prognostics (NASDAQ:SERA) & BrightSpring Health Services (NASDAQ:BTSG) Financial SurveyOctober 5, 2025 | americanbankingnews.comSera Prognostics Names Dr. Tiffany Inglis Chief Medical OfficerOctober 1, 2025 | prnewswire.comSera Prognostics: Few Takers For A Great Product Spells AngstSeptember 22, 2025 | seekingalpha.comSera Prognostics’ Earnings Call: Strategic Gains Amid Financial ChallengesSeptember 17, 2025 | theglobeandmail.comInsider Selling: Sera Prognostics (NASDAQ:SERA) CEO Sells 3,246 Shares of StockSeptember 13, 2025 | insidertrades.comInsider Selling: Sera Prognostics (NASDAQ:SERA) Director Sells 3,899 Shares of StockSeptember 11, 2025 | marketbeat.comSera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 5,263 SharesSeptember 11, 2025 | marketbeat.comSera Prognostics (NASDAQ:SERA) CEO Sells $66,647.70 in StockSeptember 11, 2025 | marketbeat.comSera Prognostics (NASDAQ:SERA) Director Sandra Aj Lawrence Sells 3,899 SharesSeptember 10, 2025 | insidertrades.comSera Prognostics Highlights Strategy at Investment ConferenceSeptember 6, 2025 | msn.comSERA PROGNOSTICS TO PRESENT AT H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCEAugust 28, 2025 | prnewswire.comRobert Gardner Harrison Sells 6,000 Shares of Sera Prognostics (NASDAQ:SERA) StockAugust 21, 2025 | insidertrades.comSera Prognostics, Inc. (NASDAQ:SERA) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comSera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilotsAugust 7, 2025 | msn.comSera Prognostics, Inc. (SERA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comSera Prognostics (SERA) Q2 Loss Down 4%August 6, 2025 | fool.comSera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comSERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSAugust 6, 2025 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025July 29, 2025 | prnewswire.comSera Prognostics director Mirza sells $552 in stockJuly 10, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Pfizer is Locking in New Growth Through a New Acquisition By Gabriel Osorio-Mazilli | September 26, 2025BDSX, DCGO, SERA, and QIPT Company DescriptionsBiodesix NASDAQ:BDSX$7.60 -0.23 (-2.94%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.DocGo NASDAQ:DCGO$1.17 -0.03 (-2.17%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Quipt Home Medical NASDAQ:QIPT$2.40 -0.10 (-3.80%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.Sera Prognostics NASDAQ:SERA$3.03 -0.17 (-5.31%) As of 02:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.